Eton Pharmaceuticals, Inc.
A maker of rare-disease treatments for children and adults, Eton Pharmaceuticals markets FDA-approved products including INCRELEX for growth disorders and ALKINDI SPRINKLE, a first-of-its-kind granular hydrocortisone for kids with adrenal insufficiency. Born in 2017 as a spinoff from Imprimis Pharmaceuticals, the Deer Park, Illinois company reworks existing medicines into friendlier forms—like a needle-free ZENEO autoinjector that blasts an emergency dose through the skin in a fraction of a second.
Sold 220.0K
Granted 32.2K
Granted 112.8K · Sold 125.0K
Granted 50.0K · Sold 50.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Brynjelsen SeanPresident & CEO, Director · 6 transactions | -66.7% | 961.2K | — | — | 220.0K |
| Riedel Norbert GDirector · 2 transactions | +6.5% | 204.6K | 32.2K | — | — |
| Krempa DavidChief Business Officer · 12 transactions | -94.1% | 37.0K | 112.8K | — | 125.0K |
| Adams Jennifer McKieDirector · 2 transactions | — | 0 | 50.0K | — | 50.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -395.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.